Emerging amyloid disease-modifying drugs for Alzheimer's disease

Expert Opinion on Emerging Drugs

Volumn 21, Issue 1, 2016, Pages 5-7

  Galimberti, Daniela ^a   Scarpini, Elio ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADUCANUMAB; ALZHEIMER DISEASE VACCINE; AMYLOID DISEASE MODIFYING DRUG; BAPINEUZUMAB; CHEMICALS AND DRUGS; CRENEZUMAB; GANTENERUMAB; HOMOTAURINE; SOLANEZUMAB; UNCLASSIFIED DRUG; VANUTIDE CRIDIFICAR; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; EDITORIAL; HUMAN; MICROGLIA; NONHUMAN; PASSIVE IMMUNIZATION; SECONDARY PREVENTION; AGED; ANIMAL; COGNITIVE DYSFUNCTION; DISEASE COURSE; DRUG DESIGN; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; COGNITIVE DYSFUNCTION; DISEASE PROGRESSION; DRUG DESIGN; HUMANS;

EID: 84959547909     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2016.1146678     Document Type: Editorial

References (15)

1. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614-29.
2. Schenk D, Barbour R, Dunn W. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in PDAPP mouse. Nature. 1999;400:173-7.
3. Gilman S, Koller M, Black RS. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553-1562.
4. Holmes C, Boche D, Wilkinson D, et al. Long-term effect of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216-223.
5. Panza F, Solfrizzi V, Imbimbo BP, et al. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Rev Clin Immunol. 2014;10(3):405-419.
6. Davtyan H, Ghochikyan A, Petrushina I, et al. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. J Neurosci. 2013;33(11):4923-4934.
7. Lambracht-Washington D, Rosenberg RN. A noninflammatory immune response in aged DNA Aβ42-immunized mice supports its safety for possible use as immunotherapy in AD patients. Neurobiol Aging. 2015;36(3):1274-1281.
8. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6(8):916-919.
9. Kerchner GA, Boxer AL. Bapineuzumab. Expert Opin Biol Ther. 2010;10(7):1121-1130.
10. Samadi H, Sultzer D. Solanezumab for Alzheimer's disease. Expert Opin Biol Ther. 2011;11(6):787-798.
11. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370(4):322-333.
12. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370(4):311-321.
13. Panza F, Solfrizzi V, Imbimbo BP, et al. Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease. Expert Rev Neurother. 2014;14(9):973-986.
14. Dolfe L, Winblad B, Johansson J, et al. BRICHOS binds to a designed amyloid-forming β-protein and reduces proteasomal inhibition and aggresome formation. Biochem J. 2016;473(2):167-178.
15. Aisen PS, Gauthier S, Ferris SH, et al. Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci. 2011;7:102-111.